Patents by Inventor John Carpten
John Carpten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11866789Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: GrantFiled: August 25, 2021Date of Patent: January 9, 2024Assignee: The Translational Genomics Research InstituteInventors: Sara Byron, Jessica Aldrich, John Carpten, David Craig, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Publication number: 20220048883Abstract: The invention provides novel FGFR inhibitors based on the pyridinylpyrimidine. The invention includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.Type: ApplicationFiled: September 12, 2019Publication date: February 17, 2022Inventors: Chao Zhang, Renata Rezende Miranda, Feng Ni, John Carpten
-
Publication number: 20220042112Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: ApplicationFiled: August 25, 2021Publication date: February 10, 2022Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Sara Byron, Jessica Aldrich, John Carpten, David Craig, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Patent number: 11186875Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: GrantFiled: June 13, 2016Date of Patent: November 30, 2021Assignees: The Translational Genomics Research Institute, Mayo Foundation for Medical Education and ResearchInventors: John Carpten, David Craig, Sara Byron, Jessica Aldrich, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Patent number: 10415083Abstract: The present invention is directed to a method of detecting a genomic rearrangement in a nucleic acid sample with Long Insert Whole Genome Sequencing (LI-WGS). The method may include obtaining a nucleic acid sample and then fragmenting the nucleic acid sample (e.g., via sonication). In particular, the fragmenting may result in the production of a plurality of inserts. Thereafter, the method comprises purifying the plurality of inserts using magnetic beads and then amplifying the purified plurality of inserts. In addition, the method further comprises sequencing the purified and amplified plurality of inserts. In some aspects, the plurality of inserts have a length of between about 800 and about 1,100 base pairs.Type: GrantFiled: October 28, 2014Date of Patent: September 17, 2019Assignee: The Translational Genomics Research InstituteInventors: Winnie Liang, John Carpten, David Craig
-
Publication number: 20180171412Abstract: Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.Type: ApplicationFiled: June 13, 2016Publication date: June 21, 2018Inventors: John Carpten, David Craig, Sara Byron, Jessica Aldrich, Mitesh Borad, Alan Bryce, Michael Barrett, George Vasmatzis, Keith Stewart
-
Publication number: 20180125846Abstract: Methods of treating, and for selecting a chemotherapy regimen for treatment of cancer in a patient (FIG. 9). For example, a patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFII and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFII is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.Type: ApplicationFiled: August 1, 2017Publication date: May 10, 2018Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Mitesh Jivraj Borad, David Craig, John Carpten
-
Patent number: 9750741Abstract: Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.Type: GrantFiled: March 17, 2014Date of Patent: September 5, 2017Assignees: The Translational Genomics Research Institute, MAYO Foundation for Medical Education and ResearchInventors: Mitesh Jivraj Borad, David Craig, John Carpten
-
Publication number: 20170166981Abstract: Methods useful in the prediction and detection of a triple negative cancer subtype using biomarkers are provided herein.Type: ApplicationFiled: February 23, 2017Publication date: June 15, 2017Inventors: David Craig, Daniel von Hoff, John Carpten
-
Publication number: 20160340742Abstract: The present invention provides a method of characterizing a cancer by obtaining a sample from a subject suspected of having cancer; and determining whether a fibroblast growth factor receptor (FGFR) fusion is present in the sample, wherein the FGFR fusion comprises a FGFR locus, thereby characterizing the cancer based on the presence or absence of the FGFR fusion.Type: ApplicationFiled: February 4, 2015Publication date: November 24, 2016Applicants: Mayo Foundation for Medical Education and Research, Translational Genomics Research InstituteInventors: Rondell P. Graham, Mitesh J. Borad, Benjamin R. Kipp, Emily G. Barr Fritcher, John Carpten, David Craig
-
Publication number: 20160038492Abstract: Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.Type: ApplicationFiled: March 17, 2014Publication date: February 11, 2016Applicants: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Mitesh Jivraj Borad, David Craig, John Carpten
-
Publication number: 20150126379Abstract: The present invention is directed to a method of detecting a genomic rearrangement in a nucleic acid sample with Long Insert Whole Genome Sequencing (LI-WGS). The method may include obtaining a nucleic acid sample and then fragmenting the nucleic acid sample (e.g., via sonication). In particular, the fragmenting may result in the production of a plurality of inserts. Thereafter, the method comprises purifying the plurality of inserts using magnetic beads and then amplifying the purified plurality of inserts. In addition, the method further comprises sequencing the purified and amplified plurality of inserts. In some aspects, the plurality of inserts have a length of between about 800 and about 1,100 base pairs.Type: ApplicationFiled: October 28, 2014Publication date: May 7, 2015Inventors: Winnie Liang, John Carpten, David Craig
-
Publication number: 20140024539Abstract: Methods useful in the prediction and detection of a triple negative cancer subtype using biomarkers are provided herein.Type: ApplicationFiled: February 2, 2012Publication date: January 23, 2014Applicant: TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: David Craig, Daniel von Hoff, John Carpten
-
Publication number: 20050196796Abstract: The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.Type: ApplicationFiled: February 24, 2005Publication date: September 8, 2005Applicant: Translational Genomics ResearchInventors: Spyro Mousses, Pia Huusko, Olli-P Kallioniemi, John Carpten, David Azorsa, Jeffrey Kiefer